Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Vascular Centre of Shanghai Jiao Tong University, Shanghai, China.
Stem Cell Res Ther. 2022 Jul 26;13(1):349. doi: 10.1186/s13287-022-03037-1.
Preclinical studies have suggested that adipose-derived mesenchymal stem cells (ADSCs) transplantation can suppress abdominal aortic inflammation and aneurysm expansion through paracrine factors. Yet, the mechanism of action is not fully understood. In the present study, we further examined the function and mechanism of ADSC-derived exosomes (ADSC-exos) and their microRNA-17-5p (miR-17-5p) on the abdominal aortic aneurysm (AAA) progression.
ADSC-exos were isolated and identified. DiR and PKH67 staining were used to trace ADSC-exo in vivo and in vitro. Raw264.7 cells were applied to perform in vitro experiments, while a murine AAA model induced using angiotensin II (Ang II) was used for in vivo testing. The expression level of miR-17-5p in macrophages and Ang II-treated macrophages after ADSC-exos treatment was determined using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The target relation between miR-17-5p and thioredoxin-interacting protein (TXNIP) was identified by a dual-luciferase reporter gene assay. Artificial activation and block of experiments of miR-17-5p and TXNIP were conducted to clarify their functions in inflammation during AAA progression. The severity of AAA between groups was assessed by maximal aorta diameter, AAA incidence, survival rate, and histological stainings. Besides, inflammasome-related proteins and macrophage pyroptosis were further evaluated using western blot, RT-qPCR, and enzyme-linked immunosorbent assay (ELISA).
The ADSC-exos were isolated and identified. In vivo testing showed that ADSC-exos were mainly distributed in the liver. Meanwhile, in vitro experiments suggested that ADSC-derived exosomes were taken up by macrophages, while inside, ADSC-exos miR-17-5p decreased a TXNIP induced by Ang II by directly binding to its 3'-untranslated region (3'UTR). Furthermore, overexpression of miR-17-5p enhanced the therapeutic function of ADSC-exos on inflammation during AAA expansion in vivo, while its inhibition reversed this process. Finally, overexpressed TXNIP triggered macrophage pyroptosis and was alleviated by ADSC-derived exosomes in vitro.
ADSC-exos miR-17-5p regulated AAA progression and inflammation via the TXNIP-NLRP3 signaling pathway, thus providing a novel insight in AAA treatment.
临床前研究表明,脂肪间充质干细胞(ADSCs)移植可以通过旁分泌因子抑制腹主动脉炎症和扩张。然而,其作用机制尚不完全清楚。本研究进一步研究了 ADSC 衍生的外泌体(ADSC-exos)及其 microRNA-17-5p(miR-17-5p)对腹主动脉瘤(AAA)进展的功能和机制。
分离并鉴定 ADSC-exos。DiR 和 PKH67 染色用于在体内和体外追踪 ADSC-exo。将 Raw264.7 细胞用于体外实验,而使用血管紧张素 II(Ang II)诱导的小鼠 AAA 模型用于体内测试。用逆转录定量聚合酶链反应(RT-qPCR)测定 ADCS-exos 处理后巨噬细胞和 Ang II 处理的巨噬细胞中 miR-17-5p 的表达水平。双荧光素酶报告基因检测鉴定 miR-17-5p 与硫氧还蛋白相互作用蛋白(TXNIP)之间的靶关系。通过人工激活和阻断 miR-17-5p 和 TXNIP 的实验,阐明它们在 AAA 进展过程中炎症中的功能。通过最大主动脉直径、AAA 发生率、存活率和组织学染色评估各组 AAA 的严重程度。此外,还通过 Western blot、RT-qPCR 和酶联免疫吸附测定(ELISA)进一步评估了炎症小体相关蛋白和巨噬细胞焦亡。
分离并鉴定了 ADSC-exos。体内试验表明,ADSC-exos 主要分布在肝脏。同时,体外实验表明 ADSC 衍生的外泌体被巨噬细胞摄取,而在细胞内,ADSC-exos miR-17-5p 通过直接结合其 3'-非翻译区(3'UTR)降低 Ang II 诱导的 TXNIP。此外,miR-17-5p 的过表达增强了 ADSC-exos 在体内 AAA 扩张过程中对炎症的治疗作用,而其抑制则逆转了这一过程。最后,过表达的 TXNIP 触发了体外巨噬细胞焦亡,并被 ADSC 衍生的外泌体缓解。
ADSC-exos miR-17-5p 通过 TXNIP-NLRP3 信号通路调节 AAA 进展和炎症,为 AAA 治疗提供了新的思路。